Back to the bench: The rejuvenation of stem cell therapy-the therapeutic potential of CD133+ progenitor cells

Journal of Thoracic and Cardiovascular Surgery

Volumn 139, Issue 6, 2010, Pages 1369-1370

  Guo, Jian ^a   Li, Ren Ke ^a   Weisel, Richard D ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CD133 ANTIGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ANGIOGENESIS; BONE MARROW TRANSPLANTATION; CELL SURVIVAL; CLINICAL TRIAL; CORONARY STENT; EDITORIAL; ENDOTHELIUM CELL; HEART EJECTION FRACTION; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MESENCHYMAL STEM CELL TRANSPLANTATION; MONONUCLEAR CELL; MUSCLE REGENERATION; NONHUMAN; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; TREATMENT RESPONSE;

ANTIGENS, CD; GLYCOPROTEINS; HUMANS; PEPTIDES; STEM CELL TRANSPLANTATION; STEM CELLS;

EID: 77952321470     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2009.12.002     Document Type: Editorial

References (13)

1. Zhang Y., Wong S., LaFleche J., Crowe S., Mesana T., Suuronon E., et al. In vitro functional comparison of therapeutically relevant human vasculogenic progenitor cells used for cardiac cell therapy. J Thorac Cardiovasc Surg (2010 Feb 18) [Epub ahead of print]
2. Schachinger V., Erbs S., Elsasser A., Haberbosch W., Hambrecht R., Holschermann H., et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 355 (2006) 1210-1221
3. Lipinski M.J., Biondi-Zoccai G.G., Abbate A., Khianey R., Sheiban I., Bartunek J., et al. Impact of intracoronary cell therapy on left ventricular function in the setting of acute myocardial infarction: a collaborative systematic review and meta-analysis of controlled clinical trials. J Am Coll Cardiol 50 (2007) 1761-1767
4. Fazel S., Chen L., Weisel R.D., Angoulvant D., Seneviratne C., Fazel A., et al. Cell transplantation preserves cardiac function after infarction by infarct stabilization: augmentation by stem cell factor. J Thorac Cardiovasc Surg 130 (2005) 1310
5. Fazel S., Cimini M., Chen L., Li S., Angoulvant D., Fedak P., et al. Cardioprotective c-kit+ cells are from the bone marrow and regulate the myocardial balance of angiogenic cytokines. J Clin Invest 116 (2006) 1865-1877
6. Yousef M., Schannwell C.M., Kostering M., Zeus T., Brehm M., and Strauer B.E. The BALANCE Study: clinical benefit and long-term outcome after intracoronary autologous bone marrow cell transplantation in patients with acute myocardial infarction. J Am Coll Cardiol 53 (2009) 2262-2269
7. Reffelmann T., Konemann S., and Kloner R.A. Promise of blood- and bone marrow-derived stem cell transplantation for functional cardiac repair: putting it in perspective with existing therapy. J Am Coll Cardiol 53 (2009) 305-308
8. Stamm C., Kleine H.D., Choi Y.H., Dunkelmann S., Lauffs J.A., Lorenzen B., et al. Intramyocardial delivery of CD133+ bone marrow cells and coronary artery bypass grafting for chronic ischemic heart disease: safety and efficacy studies. J Thorac Cardiovasc Surg 133 (2007) 717-725
9. Fritzenwanger M., Lorenz F., Jung C., Fabris M., Thude H., Barz D., et al. Differential number of CD34+, CD133+ and CD34+/CD133+ cells in peripheral blood of patients with congestive heart failure. Eur J Med Res 14 (2009) 113-117
10. Mathieu M., Bartunek J., El O.B., Touihri K., Hadad I., Thoma P., et al. Cell therapy with autologous bone marrow mononuclear stem cells is associated with superior cardiac recovery compared with use of nonmodified mesenchymal stem cells in a canine model of chronic myocardial infarction. J Thorac Cardiovasc Surg 138 (2009) 646-653
11. Shake J.G., Gruber P.J., Baumgartner W.A., Senechal G., Meyers J., Redmond J.M., et al. Mesenchymal stem cell implantation in a swine myocardial infarct model: engraftment and functional effects. Ann Thorac Surg 73 (2002) 1919-1925
12. Angoulvant D., Fazel S., Weisel R.D., Lai T.Y., Fedak P.W., Chen L., et al. Cell-based gene therapy modifies matrix remodeling after a myocardial infarction in tissue inhibitor of matrix metalloproteinase-3-deficient mice. J Thorac Cardiovasc Surg 137 (2009) 471-480
13. Hare J.M., Traverse J.H., Henry T.D., Dib N., Strumpf R.K., Schulman S.P., et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult mesenchymal stem cells (Prochymal) after acute myocardial infarction. J Am Coll Cardiol 54 (2009) 2277-2286